A Compound Stomachache Capsules Against Prostate Cancer by Targeting Phosphorylated AKT1

Author: Jia YU ¹ ; Sha CHENG ¹ ; Heng LUO ¹ ; Jia YU ² ; Sha CHENG ² ; Heng LUO ² ; Yu SONG ³ ; Xiao-Qing WAN ³ ; Ying-Jiang XU ³
Author Information

1. Natural Products Research Center of Guizhou Province
2. State Key Laboratory of Function and Applications of Medical Plants, Guizhou Medical University
3. Wansheng Pharmaceutical CO. LTD
Publication Type:Journal Article
Keywords: Chinese medicinals; compound stomachache capsules; pAKT(Ser473); prostate cancer
From: Chinese Journal of Biochemistry and Molecular Biology 2023;39(11):1606-1619
CountryChina
Language:Chinese
Abstract: The development of anticancer drugs targeting AKT1 has been reported in a variety of cancers, but there are few related studies on Chinese medicinals targeting AKT1- In this study, Compound stomachache capsules (CSC) was used for inhibiting prostate cancer (PC) cells growth by targeting AKT1 in vitro and in vivo. Through mass spectrum, target prediction and bioinformatics analysis, it is found that 37 of CSC compounds have anticancer activity, and 6 compounds such as (+)-Magnoflorine, 7-hydroxycoumarin may be their main active components against prostate cancer- The results showed that CSC had significant in vitro inhibition on the growth of prostate cancer cells (P<0- 01), and the growth inhibition rate of PC3 cells reached about 35% at 80 μg/ mL- CSC also increased ROS production, and significantly promoted apoptosis (P <0- 01) and G